Alder Biopharmaceuticals is now a Lundbeck Company. For information about Alder and its pipeline, visit:
For more information about Lundbeck and their acquisition of Alder, visit:
Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.
Fundamental Change Company Notice
ALDER BIOPHARMACEUTICALS, INC. FUNDAMENTAL CHANGE COMPANY NOTICE AND OFFER TO REPURCHASE TO THE HOLDERS OF ALDER BIOPHARMACEUTICALS, INC. 2.50% Convertible Senior Notes due... LEARN MORE
The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.